Pediatric Brain Tumors Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space

February 23 11:35 2022
Pediatric Brain Tumors Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space
Pediatric Brain Tumors Market
DelveInsight’s “Pediatric brain tumors Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pediatric brain tumors, historical and forecasted epidemiology as well as the Pediatric brain tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Pediatric Brain Tumors – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Pediatric Brain Tumors – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Pediatric Brain Tumors, historical and forecasted epidemiology as well as the Pediatric Brain Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Pediatric Brain Tumors Market Report:

  • According to the American Cancer Society, brain and spinal cord tumors are the second most common cancers in children (after leukemia). They account for about 1 out of 4 childhood cancers. More than 4,000 brain and spinal cord tumors are diagnosed each year in children and teens. The incidence rate (number of tumors per 100,000 children) has not changed much in recent years.
  • Lin et al. provided insights about Japan in a Taiwan-based study and highlighted that in the pediatric group, primary malignant brain tumors are the most common cancer among those aged 0–19 years, ranging from 2.27 to 4.81 per 100,000 population. In Japan, the overall incidence of a primary malignant brain tumor in ages 0–14 years is 3.61/100,000, and the age-standardized incidence in males is 2.1–3.5 per 100,000, while in females is 1.5–2.5 per 100,000.
  • The RARECAREnet reported an annual incidence rate of 6.8 per million children (0–14 years) in Europe for the period 2000-2007 with 15–20% of all CNS tumors being Medulloblastomas. The study published by Suresh et al. highlighted that pilocytic astrocytoma was the most commonly reported tumor (22.33%) from Europe.

Key benefits of the report:

  1. Pediatric Brain Tumors market report covers a descriptive overview and comprehensive insight of the Pediatric Brain Tumors Epidemiology and Pediatric Brain Tumors  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Pediatric Brain Tumors market report provides insights on the current and emerging therapies.
  3. Pediatric Brain Tumors market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Pediatric Brain Tumors market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pediatric Brain Tumors market.

Got queries? Click here to know more about the Pediatric Brain Tumors Market Landscape.

Pediatric Brain Tumors Overview

Pediatric brain tumors are masses or growths of abnormal cells that occur in a child’s brain or the tissue and structures that are near it. Many different types of pediatric brain tumors exist, some are noncancerous (benign) and some are cancerous (malignant).

Treatment and chance of recovery (prognosis) depend on the type of tumor, its location within the brain, whether it has spread, and your child’s age and general health. Because new treatments and technologies are continually being developed, several options may be available at different points in treatment.

Pediatric Brain Tumors Market 

The dynamics of the Pediatric Brain Tumors market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Novartis, Laminar Pharmaceuticals, Ziopharm, Oncoceutics, Cellectar Biosciences, Moleculin Biotech, and others during the forecasted period 2018-2030.

Pediatric Brain Tumors Pipeline Therapies and Key Companies 

  • Everolimus: Novartis
  • LP561A1: Laminar Pharmaceuticals
  • Ad-RTS-hIL-12 plus veledimex: Ziopharm
  • ONC201: Oncoceutics
  • CLR-131: Cellectar Biosciences 
  • WP1066: Moleculin Biotech

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Pediatric Brain Tumors Patient Share (%) Overview at a Glance

5. Pediatric Brain Tumors Market Overview at a Glance

6. Pediatric Brain Tumors Disease Background and Overview

7. Pediatric Brain Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Pediatric Brain Tumors 

9. Pediatric Brain Tumors Current Treatment and Medical Practices

10. Unmet Needs

11. Pediatric Brain Tumors Emerging Therapies

12. Pediatric Brain Tumors Market Outlook

13. Country-Wise Pediatric Brain Tumors Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Pediatric Brain Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Pediatric Brain Tumors Market Outlook 2030.

Related Reports:

Pediatric Brain Tumors Pipeline 

Pediatric Brain Tumors Epidemiology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/